Celgene Corporation’s REVLIMID® has been previously approved by the USFDA for use in the treatment of patients with transfusion-dependent anemia due to Low-or- Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Last week, the company’s Supplemental New Drug Application (sNDA) for an additional indication for REVLIMID (lenalidomide) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy, has been granted approval by the USFDA.
Multiple myeloma is the second most common blood cancer in the
REVLIMID® (lenalidomide) will be available in the following strengths: 5 mg, 10 mg, 15 mg, and 25 mg capsules.
Get information about this product at the REVLIMID website or by calling the manufacturer's toll-free number at 1-888-423-5436.
Source: Celgene Corporation
.jpg)
Comment Preview